Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5441739 | 0.86 | LMNA (0.61) | KMT2AMEN1POLBMAPTKDM4E | |
| SCHEMBL6371142 | 0.83 | POLB (0.61) | KMT2AMEN1POLBMAPTTP53 | |
| SCHEMBL5444512 | 0.81 | MEN1 (0.49) | KMT2AMEN1MAPTTP53KDM4E | |
| SCHEMBL5441846 | 0.78 | KMT2A (0.71) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL5435523 | 0.78 | KMT2A (0.53) | KMT2AMEN1POLBMAPTNPC1 | |
| SCHEMBL5444351 | 0.78 | KMT2A (0.52) | KMT2AMEN1POLBKDM4ENPC1 | |
| SCHEMBL5444881 | 0.78 | MEN1 (0.48) | KMT2AMEN1POLBNPC1RAB9A | |
| SCHEMBL5441353 | 0.78 | BLM (0.55) | KMT2AMEN1MAPTRAB9A | |
| SCHEMBL5448515 | 0.78 | MEN1 (0.59) | KMT2AMEN1KDM4ENPC1RAB9A | |
| SCHEMBL5444917 | 0.78 | HTR2A (0.46) | KMT2AMEN1POLBMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | claimed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | RAF1, ARAF, JAK1 | KMT2A 1865/4885MEN1 1756/4885POLB 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.